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Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor
histology, primary site, staging, and proliferative index. The symptoms associated with carcinoid syndrome and vasoactive
intestinal peptide tumors are treated with octreotide acetate. The PROMID trial assesses the effect of octreotide LAR on the
tumor growth in patients with well-differentiated metastatic midgut NETs. The CLARINET trial evaluates the effects of
lanreotide in patients with nonfunctional, well-, or moderately differentiated metastatic enteropancreatic NETs. Everolimus has
been approved for the treatment of advanced pancreatic NETs (pNETs) based on positive PFS effects, obtained in the treated
group. Sunitinib is approved for the treatment of patients with progressive gastrointestinal stromal tumor or intolerance to
imatinib, because a randomized study demonstrated that it improves PFS and overall survival in patients with advanced
well-differentiated pNETs. In a phase II trial, pasireotide shows efficacy and tolerability in the treatment of patients with
advanced NETs, whose symptoms of carcinoid syndrome were resistant to octreotide LAR. An open-label, phase II trial assesses
the clinical activity of long-acting repeatable pasireotide in treatment-naive patients with metastatic grade 1 or 2 NETs. Even if
the growth of the neoplasm was significantly inhibited, it is still unclear whether its antiproliferative action is greater than that
of octreotide and lanreotide. Because new therapeutic options are needed to counter the natural behavior of neuroendocrine
tumors, it would also be useful to have a biochemical marker that can be addressed better in the management of these patients.
Chromogranin A is currently the most useful biomarker to establish diagnosis and has some utility in predicting disease
recurrence, outcome, and efficacy of therapy.
1. Background
Neuroendocrine tumors (NETs) originate from neuroendo-
crine cells of the diffuse endocrine system.
They are considered rare neoplasms, though their
incidence and prevalence has increased in the last ten
years [1].
According to the 2010 WHO classification [2], neuroen-
docrine neoplasms (NENs) are classified in neuroendocrine
tumors (NETs), neuroendocrine carcinomas (NECs) of small
or large cells, and mixed adenoneuroendocrine carcinomas
(MANECs), showing more than 30% of neuroendocrine cells
and nonendocrine components.
Based on the proliferative activity, assessed by mitotic
count and/or the Ki-67 index, NETs are divided into NET-
G1 (mitotic count< 2 per 10 high-power fields (HPFs) and/
or Ki-67≤ 2%) and NET-G2 (mitotic count 2–20 per 10
HPFs and/or Ki-67 3 to 20%).
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All NECs are considered G3 (mitotic count> 20 per 10
HPFs and/or Ki-67> 20).
Furthermore, NENs distinguish between well-
differentiated neuroendocrine tumors (NET-G1 and -G2) and
poorly differentiated neuroendocrine carcinomas (NEC-G3).
It is now known that the G3 NEN is a very heterogeneous
category of tumors. Morphological differentiation and Ki-67
are able to influence the prognosis of G3 groups, and there-
fore, a distinction between a well-differentiated G3 NET
and a poorly differentiated G3 NEC would be useful.
Particularly, Heetfeld et al. proposed a G3 NET cate-
gory defining NEN with well-differentiated features and
Ki-67< 55%, representing an intermediate category between
G2 NETs and NECs [3]. Considering the prognostic role,
the morphological categories that are taking place are
well-differentiated G3 NETs with Ki-67 comprised between
20% and 55% and poorly differentiated neuroendocrine
carcinomas (G3 NECs) with Ki-67> 55%, especially in the
GEP-NEN group.
The most common sites of NETs are the lung, stomach,
appendix, cecum, duodenum, pancreas, jejunum/ileum,
colon, and rectum [4].
NETs originating in the gastrointestinal tract and pan-
creas are known as gastroenteropancreatic neuroendocrine
tumors (GEP-NETs) and are more frequent in gastric fun-
dus-corpus, proximal duodenum, Vater’s papilla, pancreas,
tip of the appendix, terminal ileum, and lower rectum.
GEP-NETs constitute about 2% of all neoplasms; they are
slow-growing and indolent neoplasms [5, 6].
Gastrointestinal NETs are rising [7]; in fact there was a
7-fold increase in the last 35 years, having available
advanced endoscopic and radiological imaging [8–10].
They account for about 50–70% of all NETs [4], and they
cause several pathological conditions since they can secrete
biologically active substances leading to the development of
characteristic clinical syndromes (functioning tumors).
However, the majority of GEP-NETs are not symptom-
atic and present with metastases or symptoms of mass effect
(nonfunctioning tumors).
As GEP-NETs are a heterogeneous group of neoplasms,
they are difficult to diagnose. Many patients may present
with metastatic disease at initial diagnosis, thus having delays
in receiving effective treatment with serious impact on prog-
nosis and survival [4].
That is why it would be necessary to identify appropriate
biomarkers to improve the management of these patients.
The ideal biomarker for GEP-NETs would be pretty
specific for GEP-NETs, easily measured, able to identify both
functioning and nonfunctioning tumors, and should be
essential for treatment monitoring and disease prognosis.
Determination of serum chromogranin A (Cg A) is the
most commonly used test [11].
Elevated serum Cg A is observed in patients with
different types of endocrine tumors including carcinoid
tumors of the stomach, lung, intestine, prostate, and liver;
pheochromocytomas; parathyroid carcinomas; medullary
thyroid carcinomas; anterior pituitary tumors; pancreatico-
duodenal tumors; neural tumors; and small cell lung cancers
(SCLCs) [12–36].
Interestingly, also certain nonneuroendocrine tumors,
such as non-small-cell lung cancer (NSCLC), prostate cancer,
and breast cancer, may undergo neuroendocrine differentia-
tion and present focal expression of Cg A [12].
In addition, it is a component of dense-core synaptic
granules in many areas of the central nervous system [13, 14].
2. Granin Family and Biological Activities
Chromogranin A is a 439-residue-long glycoprotein [15, 16],
a member of a larger family of soluble secretory proteins
(granin proteins) that includes also chromogranin B
(CgB), secretogranin (Sg) II (CgC), Sg III (1B1075), Sg
IV (HISL-19), Sg V (7B2) and Sg VI (NESP55), Sg VII
(VGF), and Sg VIII (proSAAS) [12], localized in secretory
granules of neuroendocrine cells, neurons, and the adrenal
medulla [17].
These proteins enter into the rough endoplasmic cister-
nae, are transported to the trans-Golgi network (TGN), and
then are targeted into dense-core secretory granules (DCGs),
known as large dense-core vesicles (LDCVs), or into chro-
maffin granules (CGs), in the adrenal medulla.
In humans, Cg A is the precursor to several func-
tional peptides including vasostatin-1 (VST I: hCgA1–76),
vasostatin-2 (VST II: hCgA1–115), pancreastatin (PST:
hCgA357–428), catestatin (CST: hCgA352–372), and para-
statin (PARA: pCgA347–419), negatively modulating the
neuroendocrine function [18].
Cg A is also a granulogenic protein and, when it is
overexpressed in fibroblasts, induces granule-like structures
with a dense core, releasing their contents.
This hydrophilic glycoprotein is encoded by the CHGA
gene, located in chromosome 14q32.12.
The N-terminal domain of Cg A is responsible for direct-
ing Cg A into the secretory granules [19, 20] and for binding
to Sg III, the receptor for Cg A, in the presence of calcium at
the level of the pituitary cells and pancreatic beta cells and in
neuroendocrine cells [21, 22].
At the moment, a universal diagnostic technique is
unavailable and the assessment of plasma concentrations
of Cg A can be achieved by several commercial kits, such
us radioimmunoassay (RIA), enzyme-linked immunosor-
bent assay (ELISA), immunoradiometric assay (IRMA),
Western blotting, immunofluorescence microscopy, immu-
nohistochemistry, and by recent immunofluorescent TRACE
assay [23].
The first radioimmunoassay for measurement of chro-
mogranin A was introduced in 1986 [24], and the kit used
antibodies against human chromogranin A.
The IRMA assay makes use of two monoclonal
antibodies, binding the unprocessed central domain of
chromogranin A.
Conversely, the ELISA method is based on two poly-
clonal rabbit antibodies raised against a 23 kDa carboxyl-
terminal domain of human chromogranin A.
Moreover, because it may be measured from serum or
plasma, Glinicki et al. report that plasma concentrations of
Cg A would be higher than those in serum [25].
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Granins are precursor proteins that can give rise to a large
number of small bioactive peptides, involved in different
biological functions (Table 1).
The N-terminal Cg A fragment, localized within secre-
tory granules, where insulin is also present, impedes insulin
secretion from islet cells in response to glucose by blocking
calcium influx. Pancreastatin induces glycogenolysis, inhibits
the glucose-induced insulin release through an effect on G-
protein and calcium-mediated exocytosis [26, 27], and also
stimulates insulin-dependent lipogenesis but inhibits leptin
secretion [28, 29].
Sympathetic tone regulates basal plasma levels of Cg A
[30, 32] and controls both vascular tone and cardiac
contractility [32].
In effect, plasma levels of CG A and PST (357–428) are
increased in patients with essential hypertension [32–34];
conversely, plasma CST (352–372) is diminished in such
patients [35]. Furthermore, this peptide and VST I (1–76)
are involved in vasculogenesis [36], contributing to generate
also a state of hypertension.
CST is considered the most potent inhibitor of nicotine-
evoked catecholamine secretion [37, 38], and it is also a
potent vasodilator [39, 40].
The granin family is involved in the regulation of inflam-
matory response: catestatin stimulates chemotaxis of human
peripheral blood monocytes [41], with an effect comparable
to vascular endothelial growth factor (VEGF) [36].
On the contrary, the Cg A-derived peptide VST I
prevents VEGF-mediated chemotaxis [42].
Elevated serum calcium concentration and Cg A-
derived peptides act on the calcium sensors present on
the cell membrane [43]. VST I and Cg A peptides, located
in parathyroid granules, are cosecreted when the serum
calcium is low, making an inhibitory effect on parathormone
secretion [44].
In the same way, cosecretion of parathormone and Cg A
is inhibited by parastatin [45].
2.1. Causes of Elevated Chromogranin Unrelated to
Neuroendocrine Tumor. In clinical practice, there are several
nononcological conditions characterized by an increase
in Cg A serum concentration, considering potential diag-
nostic pitfalls.
The use of proton pump inhibitors and other acid-
suppressive medications causes elevated Cg A levels, as well
as in the presence of atrophic gastritis.
For this reason, the determination of blood chromogra-
nin A levels should be made after a drug-free period of at
least 7 days.
Histamine type-2 receptor antagonists may increase the
marker concentration. It is recommended to discontinue
these drugs at least 24 h before the test.
Other benign diseases of the alimentary tract affecting the
concentration of chromogranin A are pancreatitis, chronic
hepatitis, liver cirrhosis, irritable bowel, and inflammatory
bowel diseases.
Other nononcological conditions and oncological dis-
eases inducing elevations of Cg A are listed in Table 2.
2.2. Chromogranin a and NET. The National Institutes
of Health (NIH) has classified biomarkers into three
categories [46]:
(i) “Type 0”: markers of the natural history of a disease
correlate longitudinally with known clinical indices
(symptoms) over the full range of a disease state
(ii) “Type I”: capture the effects of an intervention in
accordance with the mechanism of drug action, even
though the mechanism might not be known to be
associated with clinical outcome reflects interven-
tional effects
(iii) “Type II”: considered as surrogate end points because
a change in the marker predicts clinical benefit
Optimally, a biomarker should be found uniquely in the
malignant tissue of interest and generate a positive signal that
can be measured without confounding “noise” from normal
tissues or other nonmalignant abnormalities [47].
2.2.1. Type 0 Biomarkers. Previous studies have demon-
strated elevated circulating Cg A levels in serum or plasma
of patients with neuroendocrine tumors. Chromogranin A
historically has sensitivities that range between 60 and
100% with specificities of 70–100% depending on the NET
type [48].
(1) Specificity. The principal limitation of Cg A evaluation is
the low specificity (10–35% specificity).
As previously described, Cg A is elevated in other
nonneuroendocrine neoplasia such as breast cancer,
Table 1: The granin family and biological functions mediated by Cg A-derived peptides.
Granin proteins Cg A-derived peptides Cg A-peptide-mediated biologic function
Chromogranin A (Cg A)
Chromogranin B (CgB)
Secretogranin (Sg) II (CgC)
Sg III (1B1075)
Sg IV (HISL-19)
Sg V (7B2)
Sg VI (NESP55)
VGF (Sg VII)
proSAAS (SgVIII)
Vasostatin-1 (VST I: hCgA1–76)
Vasostatin-2 (VST II: hCgA1–115)
Pancreastatin (PST: hCgA357–428)
Catestatin (CST: hCgA352–372)
Parastatin (PARA: pCgA347–419)
Regulation of glucose balance
Regulation of lipid metabolism
Regulation of cardiovascular system
Regulation of neurotrasmitter release
Regulation of the immune system
Regulation of parathormone secretion
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hepatocellular carcinoma, pancreatic cancer, colorectal can-
cer, ovarian cancer [49], and prostate cancer [50].
Cg A elevation may be caused by several gastroentero-
pancreatic diseases: autoimmune chronic atrophic gastritis
[51], inflammatory bowel disease [52], irritable bowel syn-
drome [53], chronic hepatitis, and liver cirrhosis [54].
One of the commonest causes of spuriously elevated Cg A
levels is the proton pump inhibitor (PPI) administration
[55]. As reported by Mosli et al., short-term PPI use results
in a significant increase of Cg A in serum and plasma, an
effect that is largely independent of the assay used [56]. For
this reason, PPI needs to be discontinued for 2 weeks to fully
eliminate its effect on Cg A.
Moreover, there are renal diseases increasing Cg A levels,
for example, impaired kidney function with reduced renal
clearance [57]. Heart failure, classified according to the
New York Heart Association (NYHA) scale, correlates with
elevated Cg A [58]. And not for nothing, the concentration
of chromogranin A relates with levels of brain natriuretic
peptide (BNP) [59, 60]. There is a high concentration of Cg
A also in cases of acute coronary syndromes, and if marker
levels are increased significantly, the patient’s prognosis
worsens [61]. Elevated Cg A also occurs in case of untreated
hypertension, and as the severity of the clinical condition
correlates with increased adrenergic activity, levels of
the marker are more or less increased.
There is a high concentration of Cg A in several inflam-
matory diseases, such as rheumatoid arthritis [62] and sys-
temic lupus erythematosus.
Endocrine disorders associated with elevated chromogra-
nin are pheochromocytoma, hypercortisolemia, hyperthy-
roidism, medullary thyroid cancer, hyperparathyroidism,
and pituitary tumors (except prolactinomas).
Other factors affecting Cg A levels are strenuous exercise
and food intake before the test.
(2) Cg A and Tumor Localization. Some studies have reported
an association between Cg A and tumor location. Nobels et
al. showed elevated Cg A in 100% of cases of gastrinomas,
in 80% of small bowel NETs, and in 69% of nonfunctioning
pNETs (NF-pNETs) and in the other endocrine tumors
[63]. In GEP-NETs, biomarker concentration has been mea-
sured 100 times above the upper normal limit: in detail, the
highest Cg A levels were 200 times the normal upper limit
in ileal NETs and 150 times the normal upper limit in
GEP-NETs associated with multiple endocrine neoplasia
type 1 (MEN-1) [18].
Conversely, lower Cg A levels were noted in gastric type I,
ranging from 2 to 4 times normal, whereas type II and III
gastric ECLomas had intermediate values of the marker [18].
The determination of Cg A plasma levels does not play
a key role in diagnosis of patients with colorectal NEN,
because Cg A values in colorectal NENs are not significantly
elevated [64].
Furthermore, these authors are saying that there is no
correlation between elevated plasma Cg A levels and immu-
nohistochemical positivity in the NEN tissue sections of the
colon and rectum.
In the case of lung NETs, such as primary localization,
the Cg A values were detected significantly lower than the
levels of patients with GEP tumors [65].
(3) Cg A and Tumor Differentiation/Tumor Burden. The
concentration of Cg A is correlated with the degree of neuro-
endocrine differentiation and tumor burden, especially with
liver cancer burden [66].
Table 2: Causes of Cg A elevation unrelated to NETs.
Nononcological conditions
Nonendocrine oncological disease
Benign diseases Iatrogenic conditions
Gastrointestinal diseases
Chronic atrophic gastritis
Helicobacter pylori infection
Pancreatitis
Chronic hepatitis
Liver cirrhosis
Irritable bowel
Inflammatory bowel disease
Cardiovascular diseases
Arterial hypertension
Cardiac insufficiency
Acute coronary syndrome
Giant cell arteritis
Renal diseases
Renal insufficiency
Inflammatory diseases
Chronic bronchitis
Obstructive pulmonary diseases
Systemic rheumatoid arthritis
Endocrine disease
Hyperthyroidism
Hyperparathyroidism
Proton pump inhibitors
Histamine 2 receptor antagonists
Serotonin reuptake inhibitors
Gastric carcinoma
Pancreatic carcinoma
Hepatocellular carcinoma
Pancreatic carcinoma
Breast carcinoma
Ovarian carcinoma
Prostate carcinoma
Neuroblastoma
Small cell lung cancer
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Indeed, the diagnostic accuracy of Cg Ameasurement for
GEP-NET is higher for well-differentiated tumors versus
poorly differentiated disease [67].
Furthermore, the concentration of Cg A is higher in
tumors with intense secretory activity, such as small bowel
NETs causing carcinoid syndrome [68] and in disseminated
rather than localized neoplastic disease. Several studies docu-
ment how patients with multiple liver metastatic diseases
show higher levels of Cg A than patients with limited
neoplastic disease [65, 69].
Cg A concentration must also be elevated in the case of
nonsecreting pancreatic NETs (NF-pNETs) with liver metas-
tases at diagnosis.
In a retrospective single-center clinical study, conducted
by Yang et al., Cg A values were statistically correlated with
the well-differentiated NF-pNET in the presence of hepatic
metastatic disease, even if Cg A levels were not statistically
significant between well-differentiated and poorly differenti-
ated pNETs [70].
Moreover, the authors emphasize how the Cg A concen-
tration is connected with the degree of tumor load extension.
In the NF-pNET patients recruited in the clinical trial, the
elevated Cg A value was moreover influenced by hepatic
tumor load.
Campana et al. evaluated Cg A plasma levels in patients
with several phenotypes of endocrine tumor and at different
stages of the disease, comparing with healthy participants
and patients who have chronic atrophic gastritis (CAG),
with and without enterochromaffin cell-like (ECL) hyper-
plasia while Arnold et al. evaluated Cg A distribution
in patients with NET and chronic atrophic gastritis
(Figure 1) [65, 66].
In this study, higher Cg A levels are observed in cases of
endocrine tumors than in those of healthy subjects, obtaining
a specificity of 95.8% and a sensitivity of 85.3%, using a cutoff
range of 18-19U/L.
The patients with localized tumor showed higher
levels of Cg A than CAG patients, and identifying a
cutoff range of 53-54U/L, the sensitivity was 66.5% and
specificity 71.4%.
Obviously, patients with CAG showed a marker concen-
tration higher than that of healthy participants.
These authors also noted that Cg A levels were pro-
gressively higher in the presence of advanced disease. This
increase was statistically significant comparing patients
with localized and diffuse disease. For this one, the used
cutoff range was 281-282U/L with sensitivity of 71.1% and
specificity 78.8%.
Comparing also patients with endocrine tumors with
those without tumors, they have identified a cutoff range of
31-32U/L with sensitivity of 75.3% and specificity 84.2%.
In this analysis, a significant increase of Cg A concentra-
tion was observed in patients with GEP-NET, but a signifi-
cant difference in Cg A levels was not observed in relation
to the primary localization of the GEP-NET.
However, not all NET types are characterized by a corre-
lation between Cg A elevation and extent of disease. Elevated
chromogranin A is typical in gastrinoma even without
metastases in the liver [71].
Instead, Koenig et al. conducted a study analyzing their
GEP-NEN database and focusing only on patients with
primary tumor localization in the colon and rectum [64].
The majority of tumors were well differentiated, and
more than 64% of the patients exhibited metastases at diag-
nosis (liver and lymph nodes), especially since they were
detectable in G2 and poorly differentiated G3 neoplasms.
The study demonstrated there is no correlation of plasma
level of Cg A and tumor progression in patients suffering
from colorectal NEN during follow-up [64].
2.2.2. Type I Biomarker. “Type I” biomarkers capture the
effects of an intervention in accordance with the mechanism
of drug action; even though the mechanism might not be
known to be associated with a clinical outcome, it still reflects
interventional effects.
In assessing NET therapy, a reduction of higher than 50%
or at least higher than 25% of a circulating tumor marker is
considered to represent a significant effect [72–74].
The evidence to support Cg A as such a marker of thera-
peutic efficacy is modest and controversial.
CAG
HNH
NET
DD
HD
LD
DF
Figure 1: Distribution of Cg A in patients with NET and chronic atrophic gastritis (CAG). In the NET group, higher Cg A levels are observed
in patients with diffuse disease (DD) compared with patients with local (LD) or hepatic (HD) disease. In the disease-free patients (DF), Cg A
levels were the lowest of all. In the CAG group, higher Cg A levels are observed in patients with hyperplasia (H) of ECL cells, compared with
patients without hyperplasia [66].
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In a study enrolling patients with progressive, metastatic
NETs, including GEP-NETs, conducted by Faiss et al., the
therapy with lanreotide 1mg three times daily or inter-
feron-α (INF-α) 5× 106U three times weekly or lanreotide
1mg three times daily + INF-α 5× 106U three times weekly
had not given significant Cg A reduction among treatment
groups and the biochemical response did not correlate with
inhibition of tumor growth [75].
In patients with metastatic, well-differentiated GEP-
NETs, examined by Arnold et al., sudden rapid increase in
Cg A to >1000U/L was associated with increased hepatic
tumor burden and rapid disease progression [66].
In a retrospective study of patients with NET, Cg A
levels were the first indication of the recurrence disease
after radical surgery [76]. The authors argued that its peri-
odic measurement may be useful in detecting recurrence
of the neoplasm.
Another study, conducted by Bajetta et al., showed that
progression of the disease correlated with elevated Cg A con-
centrations in 83% of patients with GEP-NETs of different
sites and in 100% of cases in patients with liver metastasis
progression [77].
Brizzi et al. enrolled twenty-nine patients with locally
advanced or metastatic NETs, including GEP-NETs, with
radiologic confirmation of progressive disease. The treatment
with octreotide LAR and 5-fluorouracil (5-FU) resulted in
increased CgA> 25% in two of twenty-five evaluable patients,
stable disease in eleven patients, Cg A decrease≥ 50% in eight
of them, and complete response in four patients [78].
Vezzosi et al. enrolled 46 patients with metastatic well-
differentiated GEP-NETs in a prospective study with
follow-up. In 16/32 patients (50%), an increase of Cg
A≥ 25% is associated with tumor stable disease (SD) or
tumor partial response (PR) (sec. Response Evaluation Cri-
teria In Solid Tumors, RECIST criteria). This study does not
validate Cg A as a surrogate marker of tumor progression
according to RECIST criteria [79].
As somatostatin analogs decrease Cg A synthesis and
secretion, the decreased blood measurements likely reflect
antisecretory rather than antiproliferative effects. It is unclear
whether inhibition of a secretory marker can be an effective
clinical marker of cell proliferation (tumor progression).
Jacobs et al. conducted a study in which patients with
metastatic, well-differentiated NETs were treated with evero-
limus 5mg or 10mg daily plus octreotide LAR 30mg every
28 days. An early Cg A response (≥30% decrease from base-
line at week 4) was observed in 77% of patients with PR,
in 46% of patients with SD/progressive disease (PD), and
also in 83% of carcinoid patients with tumor PD, in 38%
of carcinoid patients with tumor SD/PD, and in 71% and
55% of islet-cell NET patients with tumor PR and SD/
PD [80].
In the RADIANT-1 study, the Cg A response to the treat-
ment was evaluated in addition to the baseline biomarker
assessment [81]. Cg A response to everolimus occurred in
51% of patients, and an early Cg A response to the drug
was observed in 47% of patients with elevated baseline levels.
As a potential predictor of treatment outcomes, patients with
early Cg A response had RECIST partial response. In patients
with Cg A levels greater than the upper limit of the normal,
measurable tumor reduction occurred in 87.1%.
In conclusion, an early Cg A response can be useful as a
potential predictor of treatment outcome in patients with
advanced pNET treated with everolimus.
According to the study conducted by Yang et al., the
therapeutic response of NF-pNETs consisted of a reduction
of Cg A concentration, associated with PR and complete
response in patients with this type of cancer. Contrarily,
patients regarded as having progression disease or relapse
had increased Cg A levels (Figure 2) [70].
Therefore, a sudden and rapid increase in serum Cg A in
patients with metastatic disease should be considered as an
indicator of tumor progression.
Conversely, Cg A is a very poor plasma marker for
follow-up patients suffering from colorectal NENs [64].
Even after confirmed progression of hepatic disease,
plasma levels of Cg A were not slightly elevated (Figure 3).
2.2.3. Type II Biomarker. “Type II” biomarkers are consid-
ered as surrogate end points because a change in the marker
predicts clinical benefit.
In a retrospective study of a mixed cohort of NETs, an
early Cg A decrease after treatment was positively correlated
with survival rate [82].
In patients with nonfunctioning GEP-NETs, located in
the pancreas, midgut (small intestine and appendix), hindgut
(large intestine, rectum, anal canal, and anus), or of unknown
origin, Cg A levels are reduced with respect to baseline in the
presence of treatment with lanreotide autogel at the dose of
120mg (LAN), whereas in placebo patients, Cg A concentra-
tion increased from baseline [83]. Progression-free survival
(PFS) is also significantly longer for patients receiving LAN;
therefore, an increase of biomarker levels leads to a reduction
in PFS.
In the prospective phase II study, patients with advanced
low- to intermediate-grade NETs were enrolled to receive
everolimus [4]. The trial showed that median PFS for patients
with elevated baseline Cg A was 8.34 months and median
overall survival (OS) was 16.95 months [81]. In addition,
the data suggest that in patients with normal Cg A/elevated
neuron-specific enolase (NSE), median PFS was shorter than
in those with elevated Cg A/normal NSE. Median OS was
worse when baseline Cg A and NSE were elevated compared
with normal baseline Cg A and NSE. Early Cg A response
was associated with longer median PFS (13.31 months),
and the same goes for OS (24.90 months).
Normalization or ≥30% decrease of Cg A levels with
everolimus monotherapy also significantly increased median
PFS and OS. In conclusion, this study showed that elevated
baseline Cg A levels significantly reduced OS in patients with
advanced pNETs.
In pNET patients, enrolling in the RADIANT-2 trial,
baseline elevated Cg A levels correlated with reduced PFS,
whereas early Cg A responses were associated with signifi-
cantly increased PFS, regardless of treatment [84].
In patients with low- or intermediate-grade advanced
pNETs, receiving everolimus or placebo, elevated baseline
Cg A determined a decrease of PFS, but the inhibitor of
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mammalian target of rapamycin improved progression-free
survival regardless of baseline Cg A.
However, higher baseline levels of Cg A were associated
with shorter PFS, showing that this marker was a poor prog-
nostic factor of survival in patients with pNETs [85, 86].
In a study conducted by Cives et al., normal baseline Cg
A correlated with median PFS of 18.5 months and elevated
baseline Cg A levels, with subsequent normalization or
reduction≥ 50% within three months from the initiation of
the treatment, were associated with a median PFS of 11.8
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Figure 3: Plasma Cg A in patients with confirmed progression of colorectal NENs. Baseline levels and concentration of Cg A during follow-
up of patients with metastatic colorectal NENs is no different (a) as observed during small bowel neuroendocrine tumor progression (b) [65].
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Figure 2: Early Cg A response as potential predictor of treatment outcome. In the RADIANT-1 study, patients with early Cg A response
experience longer median progression-free survival (13.31 months) (a), whereas median overall survival is 24.90 months (b) [82]. A study
in patients with NF-pNETs shows that a reduction of Cg A concentration is correlated with better prognosis in this group of patients (c) [71].
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months, whereas the median PFS was 5.7 months for late and
nonresponders [87].
(1) Prognostic Role. A prognostic role of Cg A in patients with
GEP-NETs is described in the literature; in effect, high levels
should correlate with shorter survival.
Retrospective studies have noted an association between
Cg A levels and time survival in patients with metasta-
tic GEP-NETs [66], pNETs [88], and nonfunctioning
pNETs [89].
According Janson et al., a concentration of Cg
A> 5000mg/L is an independent predictor of shorter sur-
vival in patients with midgut carcinoids [69]; in fact, patients
with Cg A less than 5000mg/L have longer median survival
(57 months) compared to patients with higher marker values
(33 months).
At diagnosis of GEP-NET patients, an indicative predic-
tor of shorter survival is a Cg A concentration in excess of
three times the upper limit of the normal [88].
Modlin et al. report that tumor location and the concen-
tration of chromogranin A do not always affect patient
survival, because it is not true that the marker correlates
positively with diminished survival [90].
To investigate the prognostic value for OS of Cg A in
patients suffering from NF-pNETs, subjects with elevated
concentration of the marker showed a lower OS than
those with normal or decreased Cg A levels during the
follow-up [70].
Koenig et al. showed that Cg A plasma levels are not
sufficient to predict overall survival in patients with NENs
of the colon and rectum [64].
3. Conclusions
Chromogranin A is a widely used biomarker for the assess-
ment of neuroendocrine neoplasms, especially for the diag-
nosis and management of those of gastroenteropancreatic
origin.
Generally, the sensitivity of this nonspecific marker test
varies in different neoplasms, ranging from 10% to 100%
and its specificity is from 68% to 100% [11].
The sensitivity of Cg A in the diagnosis of NETs depends
on the degree of neoplasm differentiation, on the primary site
and on the extent of the disease.
However, it is important to stress that the sensitivity and
specificity to measurement of Cg A differ between the used
commercial kits.
Because chromogranin A concentration correlates with
the secretory activity of functioning tumors, a reduction of
marker levels may occur during treatment with antiprolifer-
ative somatostatin analogue reflecting the inhibition of the
secretory activity of the tumor rather than an antitumor
effect [84].
Cg A levels cannot be used to diagnose or follow up the
wide majority of patients with NENs of the colon and rectum,
considering that Cg A is rarely elevated in this kind of
patients, does not reflect tumor burden, and does not predict
survival in these subjects [64].
Most likely, this occurs because Ec cells, expressing large
amounts of Cg A, are much less frequent in the colon than in
the small bowel.
Conversely, L cells, expressing small amounts of Cg A,
occur mostly in the large intestinum and increase along
the colon.
Several clinical trials show how higher baseline levels of
Cg A are associated with shorter PFS and how an early
response (a 30% or greater decrease from baseline or normal-
ization after 4 weeks of treatment) correlates with longer PFS
(13.3 mo versus 7.5 mo; HR=0.25; P< 0.001) and longer OS
(24.9 mo versus 12.7 mo; HR=0.4; P=0.01) [81].
In the phase III RADIANT-2 study, it has been con-
firmed that early decrease of Cg A concentration can repre-
sent a marker of PFS in patients on everolimus [91].
Other clinical trials have indicated the Cg A levels as a
prognostic factor, including a prospective, double-blind, ran-
domized, multicenter, phase III study (RADIANT III), which
confirmed that elevated Cg A is a poor prognostic factor of
survival in patients suffering from pNETs [92].
There are no comparable data for patients with GEP-
NETs in treatment with sunitinib right now.
The measurement of chromogranin A should not be
recommended in our daily clinical practice and could be used
with caution because it has also been implicated in various
benign and malignant diseases.
Cg A concentration is also a useful diagnostic biomarker
in NF-pNETs and it correlates with the degree of differentia-
tion, primary diameter of NF-pNET, and hepatic metastatic
progression [70].
The assessment of circulating Cg A levels can be used as a
diagnostic tool for the prediction of NETs in different treat-
ment periods because it occurs a downward trend in the case
of complete response.
Although limitations exist, Cg A levels and their change
during specific therapies are prognostic, while diagnostic
accuracy for GEP-NETs would seem to be higher for func-
tioning versus nonfunctioning, well versus poorly differenti-
ated, and metastatic versus locoregional disease.
In several clinical trials recruiting patients suffering from
thoracic neuroendocrine tumors (tNETs), the tumor grade,
treatment method, and Cg A status show significant correla-
tion with survival [93].
Poor prognostic factors include not only a high grade of
tNETs and incomplete resection but also a Cg A-positive
status.
It is important to stress that generally the Cg A levels of
patients with tNETs are significantly lower than the ones
found in GEP-NETs.
Therefore, Cg A is also a poor predictive factor for tNETs.
It is also true that patients with lung NETs were enrolled
in several clinical trials described above.
The results of the multivariate analysis show that
baseline serum Cg A levels more than 10 times the upper
limit of the normal are predictive factors of a shorter time
to radiological progression and of a poor response to
treatment [94].
In a phase III study (RADIANT-2), 15% of the NETs
receiving treatment regimen including everolimus plus
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octreotide LAR occurred in the lung and a therapeutic
efficacy correlated with greater reductions in serum chromo-
granin A [95].
Measurement of Cg A should be used to evaluate
response to therapy or disease progression after all, rather
than early diagnosis or recurrence.
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